What was the study about?

Primary sclerosing cholangitis (PSC) is a complex condition that progresses differently in every person, making it very difficult for doctors to predict who will face severe complications, such as needing a liver transplant or facing death. This difficulty makes it hard to plan regular medical check-ups and design effective clinical trials for new drugs.

The researchers wanted to find out if combining multiple blood markers, which measure different disease processes like tissue scarring (fibrosis), inflammation, and gut bacterial metabolism, could create a more accurate risk-prediction tool than using single tests or existing clinical calculating tools.

How was it done?

The researchers gathered blood samples and clinical data from a large international group of 906 people with PSC across Norway, Sweden, and the United States.

They tested the blood samples for a panel of eight specific biological markers. They then tracked the patients over several years to see who required a liver transplant or passed away within a two-year and five-year window. Using statistical models, they tested how accurately the eight-marker combination could predict these outcomes, and then checked if they could simplify it into a shorter, more practical test.

What were the key findings?

• The Full Test Was Highly Accurate: A mathematical score combining all eight blood markers proved highly accurate at predicting whether a patient would remain alive and transplant-free at both the two-year and five-year marks.
• A Simplified, Practical Alternative Worked Just as Well: The researchers discovered they could shorten the test to just three key markers and get nearly the same highly accurate results. This model focuses on three specific indicators:
  1. ELF (Enhanced Liver Fibrosis test): Measures tissue scarring.
  2. KTR (Kynurenine-Tryptophan ratio): Measures immune system inflammation.
  3. PLP (Pyridoxal 5′-phosphate): Reflects gut bacterial metabolism and vitamin levels.
• Outperforming Current Tools: Both the full eight-marker test and the simplified three-marker test were significantly more accurate at predicting patient outcomes than the standard ELF test alone, or existing clinical calculators (such as the Amsterdam-Oxford PSC model and the PRESTO tool).

Conclusion

The study shows that combining blood markers that reflect entirely different aspects of PSC, such as scarring, inflammation, and gut health, gives a much clearer picture of how a person's condition is likely to progress. By outperforming current risk calculators, this new multi-marker approach could eventually help doctors provide more personalised care and help researchers design better, more targeted clinical trials for PSC.

Reference

Helgadottir H, Braadland PR, Ali A, Atkinson E, Juran BD, McCauley B, Fossdal G, Folseraas T, Tjønnfjord S, Boberg KM, Karsdal M. OS-006-YI Development of a multi-biomarker model to predict transplant-free survival in primary sclerosing cholangitis: a multicenter retrospective study. Journal of Hepatology. 2026 May 1;84:S13.